title: The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
abstract: The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT) treatment decisions has been evaluated in many previous studies. However, it can be difficult to interpret the collective findings, which were conducted in diverse settings with limited sample sizes. We conducted a systematic review and meta-analysis to synthesize the results and provide insights about ODX utility. Studies, identified from PubMed, Embase, ASCO, and SABCS, were included if patients had ER+, node -, early-stage breast cancer, reported use of ODX to inform actual ACT decisions. Information was summarized and pooled according to: (1) distribution of ODX recurrence scores (RS), (2) impact of ODX on ACT recommendations, (3) impact of ODX on ACT use, and (4) proportion of patients following the treatment suggested by the ODX RS. A total of 23 studies met inclusion criteria. The distribution of RS categories was 48.8 % low, 39.0 % intermediate, and 12.2 % high (21 studies, 4,156 patients). ODX changed the clinical-pathological ACT recommendation in 33.4 % of patients (8 studies, 1,437 patients). In patients receiving ODX, receipt of ACT were: 28.2 % overall, 5.8 % low, 37.4 % intermediate, and 83.4 % high. Low RS patients were significantly more likely to follow the treatment suggested by ODX versus high RS patients RR: 1.07 (1.01–1.14) [corrected].The pooled results are consistent with most individual studies to date. The increased proportion of intermediate scores relative to original estimates may have implications for the clinical utility and cost impacts of testing. In addition, low versus high RS patients were significantly more likely to follow the ODX results, suggesting a tendency toward less aggressive treatment, despite a high ODX RS. Finally, there was a lack of studies on the impact of ODX on ACT use versus standard approaches, suggesting that additional studies are warranted.
authors: Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, Box 357630, Seattle, WA 98195-7630, USA. carlsojj@uw.edu
authors: Josh J
authors: JJ
authors: Carlson
authors: Joshua A
authors: JA
authors: Roth
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015986:Confounding Factors, Epidemiologic; D016208:Databases, Factual; D004967:Estrogens; D005260:Female; D020869:Gene Expression Profiling / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D052138:Genes, Neoplasm; D006801:Humans; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000191:economics / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D018579:Patient Selection; D011379:Prognosis; D017594:Publication Bias; D011960:Receptors, Estrogen / Q000032:analysis; D018570:Risk Assessment
chemical_list: D004967:Estrogens; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen
references: Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
references: 19622511
references: J Clin Oncol. 2010 Apr 1;28(10):1677-83
references: 20065188
references: Lancet. 2005 May 14-20;365(9472):1687-717
references: 15894097
references: J Oncol Pract. 2007 Jul;3(4):182-6
references: 20859407
references: Cancer Control. 2010 Jul;17(3):177-82
references: 20664515
references: Nat Rev Clin Oncol. 2010 Dec;7(12):725-32
references: 20975745
references: J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92
references: 16954471
references: Cancer. 2008 Feb 15;112(4):731-6
references: 18076012
references: Mol Diagn Ther. 2009;13(2):73-90
references: 19537843
references: N Engl J Med. 2004 Dec 30;351(27):2817-26
references: 15591335
references: Evid Rep Technol Assess (Full Rep). 2007 Dec;(160):1-105
references: 18457476
references: Genet Med. 2009 Jan;11(1):66-73
references: 19125125
references: J Oncol Pract. 2011 May;7(3 Suppl):e38s-45s
references: 21886510
references: Am J Surg. 2008 Oct;196(4):527-9
references: 18809056
references: J Surg Oncol. 2009 May 1;99(6):319-23
references: 19204954
references: J Clin Oncol. 2007 Nov 20;25(33):5287-312
references: 17954709
references: JAMA. 1999 Sep 15;282(11):1054-60
references: 10493204
references: Genet Med. 2005 Jul-Aug;7(6):380-9
references: 16024969
references: Am J Manag Care. 2011 May 01;17(5 Spec No):e194-202
references: 21711071
references: Am J Epidemiol. 1994 Aug 1;140(3):290-6
references: 8030632
references: Lancet. 2012 Feb 4;379(9814):432-44
references: 22152853
references: J Clin Oncol. 2011 Dec 10;29(35):4611-9
references: 22067390
references: Lancet. 2012 Mar 3;379(9818):823-32
references: 22285053
references: Cancer. 2010 Nov 15;116(22):5161-7
references: 20665886
references: Breast. 2013 Apr;22(2):109-120
references: 23462680
references: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references: 16720680
references: Biometrics. 2000 Jun;56(2):455-63
references: 10877304
references: Breast Cancer Res Treat. 2011 May;127(1):133-42
references: 21221771
references: J Clin Oncol. 2012 Sep 1;30(25):3058-64
references: 22869890
references: Breast Cancer Res Treat. 2009 Jan;113(2):275-83
references: 18311582
references: Breast Cancer Res Treat. 2011 Apr;126(3):797-802
references: 21197567
references: Cancer. 2012 Feb 1;118(3):788-96
references: 21720988
references: Oncologist. 2011;16(11):1520-6
references: 22016474
references: Ann Intern Med. 2008 Mar 4;148(5):358-69
references: 18252678
references: Cancer. 2010 Apr 15;116(8):1992-2000
references: 20213682
references: Ann Oncol. 2011 Nov;22(11):2381-2386
references: 21363879
references: J Clin Oncol. 2010 Apr 1;28(10):1671-6
references: 20065191
references: Value Health. 2010 Jun-Jul;13(4):381-7
references: 20412544
references: J Clin Oncol. 2008 Feb 10;26(5):721-8
references: 18258979
references: Am J Manag Care. 2005 May;11(5):313-24
references: 15898220
references: Ann Surg Oncol. 2011 Nov;18(12):3399-406
references: 21537874
references: Breast. 2009 Oct;18 Suppl 3:S141-5
references: 19914534